Summary of minutes of EUCAST Steering Committee Meeting
Brussels, Belgium 25-26 November 2013

At attending

Dr Derek F.J. Brown  DB  Scientific Secretary  United Kingdom
Dr Rafael Cantón  RC  Chairperson  Spain
Prof Luc Dubreuil  LD  CA-SFM  France
Dr Christian Giske  CG  SRGA  Sweden
Dr Robin Howe  RH  BSAC  UK
Prof Gunnar Kahlmeter  GK  Clinical Data Co-ordinator  Sweden
Prof Luis Martínez-Martínez  LM  EUCAST General Committee  Spain
Prof Johan W. Mouton  JM  CRG  The Netherlands
Prof Sören Gatermann  SG  EUCAST General Committee  Germany
Dr Martin Steinbakk  MS  NWGA  Norway
Dr Robert Skov  RS  EUCAST General Committee  Denmark

Visiting members

Prof John Turnidge  JT  AUSNAC  Australia

Apologies

Prof Alasdair P. MacGowan  AM  BSAC  United Kingdom

1 Chairman’s welcome

RH was present as BSAC representative in place of AM.

2 Minutes of meeting of 23-24 September 2013

With minor corrections the minutes were accepted as a correct record.

3 Matters arising from minutes of 23-24 September 2013 (items not covered by agenda)

The Australian NAC has provided exception notes for cefuroxime axetil with *H. influenzae* and for cefazolin with Enterobacteriaceae.

4 New agents

For delamanid, following the re-assessment by EMA a positive opinion has been given. For ceftobiprole, the MHRA has given a positive response. EUCAST breakpoints will be adopted for both agents. There were no negative comments from the consultation on EUCAST proposals for doripenem breakpoint revision and revised breakpoints will be incorporated into the 2014 breakpoint tables, version 4.0. Final EUCAST proposals for a new antimycobacterial agent have been made.

5 EUCAST rationale documents

A rationale document for ceftaroline is being prepared. The format of rationale documents is being updated.

6 Subcommittees

The secretary of the antifungal susceptibility testing subcommittee has resigned as secretary and possible replacements are being considered. Spanish translations of EUCAST documents 7.2 and 9.1 on antifungal susceptibility testing have been released on the website. Guidelines for the detection of resistance mechanisms of clinical and/or epidemiological importance are close to completion.

Breakpoint issues

7 Proposed changes to breakpoint tables for version 4.0 were reviewed. A preliminary version will be released early in December 2013.

For *Neisseria meningitidis* penicillin breakpoints will be retained unless convincing evidence for change is provided. Ciprofloxacin breakpoints are under review.

The wide consultation on amoxicillin-clavulanic acid breakpoints for Enterobacteriaceae in UTI showed general agreement and breakpoints will be included in version 4.0 of breakpoint tables.

For *Acinetobacter* spp., sulbactam, ceftazidime and piperacillin-tazobactam breakpoints are being considered.

The international review of colistin breakpoints is continuing.
A pefloxacin disk diffusion screen will be introduced to detect resistance to fluoroquinolones in *Salmonella* spp.

Guidelines for detection of dissociated macrolide resistance with the D test will be included in version 4.0 of breakpoint tables and revised guidance on interpretation will be provided.

Problems with the expert rules for *Serratia marcescens* and aminoglycosides were noted and these will be reviewed in 2014.

Following difficulties in agreeing breakpoints for topical agents a technical note explaining the issues is being drafted.

Expert rules will be updated in 2014.

The aztreonam ECOFFs and breakpoints for *Pseudomonas* were discussed.

Data supporting EUCAST disk diffusion breakpoints for high level streptomycin resistance in enterococci were reviewed and breakpoints were confirmed.

It is planned to discuss various aspects of breakpoints for *N. gonorrhoeae* with European groups.

Guidelines for manufacturers on data required for new antimycobacterial agents are being considered.

Following wide consultation it was agreed to remove cefaclor breakpoints for *H. influenzae* and *M. catarrhalis*.

Following review and agreement of changes to breakpoints for doripenem it was agreed to apply the same principles to breakpoints for other carbapenems.

**Organisms without EUCAST breakpoints** Recommendations for testing *Actinomyces* spp. are being prepared.

**EUCAST methods** Due to lack of wide availability of the proposed QC strain *H. influenzae* NCTC 8648, alternative strains are being investigated.

**Implementation of EUCAST breakpoints** No new information.

**EUCAST MIC and zone diameter distribution website** Planned changes are yet to be implemented.

**Publications and presentations** Papers explaining ECOFFs, reporting as found for Enterobacteriaceae and uptake of EUCAST breakpoints are being prepared. A paper on calibration and validation of the disk diffusion method has been submitted for publication in CMI.

**NACs** It is noted that additional countries outside Europe are considering setting up NACs and adopting EUCAST breakpoints.

**EUCAST SOPs** SOPs on EUCAST minutes and on update and format of EUCAST documents are being prepared.

**ESCMID** No new information.

**EMA** No new information.

**CLSI** No new information.

**ECDC** No new information.

**Telavancin** Susceptibility testing methods and breakpoints are being reviewed.

**International MIC and zone diameter distribution website** Approaches to a proposed
international website mirroring the EUCAST site are being considered.

21 **Any other business** It was noted that the EU is setting up advisory committees on test systems but this should not have an impact on EUCAST.

22 **Next meetings**
10-11 February 2014, Dusseldorf, Germany.
13-14 May 2014, Barcelona, Spain (immediately following ECCMID).
15-16 September 2014, Linz, Austria.
10-11 November 2014, Basel, Switzerland.
16-17 February 2015, Brussels, Belgium.
28-29 April 2015, Copenhagen, Denmark (immediately following ECCMID)

Ratified summary of minutes of meeting 25-26 November 2013. Prepared by DB, RC and GK